The MTC and partnership revenue alone validate this share price a year from now. There has been nothing to discourage the notion that Cabo will become a fundamental component of cancer care across a broad range of applications. I would love to hear a rational short argument for this stock that doesn't consist of a byline and 'eom.'
You won't hear any rational short comments here. They are all still wearing their spyder man PJ's. The eom boy has his 14th birthday this week and his daddy is going to get him his own computer and a set of gerranimals so he can dress himself in the morning. You got to admit, they are fun to laugh at!